Prophylactic Therapy With Valgancyclovir in High-Risk (Cytomegalovirus D+/R-) Liver Transplant Recipients: A Single-Center Experience

Transplantation Proceedings

Volumn 41, Issue 6, 2009, Pages 2189-2191

  Montejo, M ^a   Montejo, E ^a   Gastaca, M ^a   Valdivieso, A ^a   Fernandez, J R ^a   Testillano, M ^a   Gonzalez, J ^a   Bustamante, J ^a   Ruiz, P ^a   Suarez, M J ^a   Ventoso, A ^a   Rubio, M C ^a   de Urbina, J Ortiz ^a  

^a HOSPITAL DE CRUCES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

VALGANCICLOVIR;

ADULT; ARTICLE; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HIGH RISK PATIENT; HUMAN; LEUKOPENIA; LIVER TRANSPLANTATION; MALE; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; VIRUS HEPATITIS;

ADULT; ANTIVIRAL AGENTS; CHEMOPREVENTION; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOPENIA; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TACROLIMUS;

EID: 68949204228     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2009.06.005     Document Type: Article

References (16)

1. Kanj S.S., Sharara A.I., Clavien P.A., et al. Cytomegalovirus infection following liver transplantation: review of the literature. Clin Infect Dis 22 (1996) 537
2. Evans P.C., Soin A., Wreghitt T.G., et al. An association between cytomegalovirus infection and chronic rejection after liver transplantation. Transplantation 69 (2000) 30
3. Paya C., Humar A., Dominguez E., et al. Efficacy and safety of valganciclovir vs oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 4 (2004) 611
4. Limaye A.P., Bakthavatsalam R., Kim H.W., et al. Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis. Transplantation 78 (2004) 1390
5. Ljungman P., Griffths P., and Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 34 (2002) 1094
6. Cytomegalovirus. Am J Transplant 4 suppl 10 (2004) 51
7. Limaye A.P., Bakthavatsalam R., Kim H.W., et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 81 (2006) 1645
8. Jain A., Orloff M., Kashyap R., et al. Does valganciclovir hydrochloride (Valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?. Transplant Proc 37 (2005) 3182
9. Berkman S.C., Asheraft E., Baillie M., et al. Valganciclovir for CMV prophylaxis in liver transplant recipients: an initial experience. Am J Transplant 4 suppl 8 (2004) 358
10. Arthurs S.K., Eid A.J., Pedersen R.A., et al. Delayed-onset primary cytomegalovirus disease after liver transplantation. Liver Transpl 13 (2007) 1703
11. Humar A., Paya C., Pescovitz M.D., et al. Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R- solid organ transplant recipients. Am J Transplant 4 (2004) 644
12. Razonable R.R. Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients. Am J Health Syst Pharm 62 suppl 1 (2005) S7
13. Kijpittayarit S., Deziel P., Eid A.J., et al. Primary cytomegalovirus disease after five years of antiviral prophylaxis. Transplantation 81 (2006) 137
14. Singh N., Wannstedt C., Keyes L., et al. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease. Transplantation 79 (2005) 85
15. Diaz-Pedroche C., Lumbreras C., San Juan R., et al. Valganciclovir preemptive therapy for the prevention of cytomegalovirus disease in high-risk seropositive solid-organ transplant recipients. Transplantation 82 (2006) 30
16. Singh N., Wannstedt C., Keyes L., et al. Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts. Liver Transpl 14 (2008) 240